263 related articles for article (PubMed ID: 18155883)
1. Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles.
Ahmad Z; Pandey R; Sharma S; Khuller GK
Int J Antimicrob Agents; 2008 Feb; 31(2):142-6. PubMed ID: 18155883
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
Pandey R; Khuller GK
J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis.
Sharma A; Pandey R; Sharma S; Khuller GK
Int J Antimicrob Agents; 2004 Dec; 24(6):599-604. PubMed ID: 15555884
[TBL] [Abstract][Full Text] [Related]
4. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
Sharma A; Sharma S; Khuller GK
J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-based oral drug delivery system for an injectable antibiotic - streptomycin. Evaluation in a murine tuberculosis model.
Pandey R; Khuller GK
Chemotherapy; 2007; 53(6):437-41. PubMed ID: 17952004
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis.
Ahmad Z; Sharma S; Khuller GK
Nanomedicine; 2007 Sep; 3(3):239-43. PubMed ID: 17652032
[TBL] [Abstract][Full Text] [Related]
7. Oral poly(lactide-co-glycolide) nanoparticle based antituberculosis drug delivery: toxicological and chemotherapeutic implications.
Pandey R; Sharma S; Khuller GK
Indian J Exp Biol; 2006 Jun; 44(6):459-67. PubMed ID: 16784116
[TBL] [Abstract][Full Text] [Related]
8. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential.
Ahmad Z; Pandey R; Sharma S; Khuller GK
Indian J Chest Dis Allied Sci; 2006; 48(3):171-6. PubMed ID: 18610673
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis.
Kumar G; Sharma S; Shafiq N; Pandhi P; Khuller GK; Malhotra S
Drug Deliv; 2011 Jan; 18(1):65-73. PubMed ID: 20735202
[TBL] [Abstract][Full Text] [Related]
10. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
[TBL] [Abstract][Full Text] [Related]
11. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis.
Ahmad Z; Sharma S; Khuller GK
FEMS Microbiol Lett; 2006 Aug; 261(2):181-6. PubMed ID: 16907718
[TBL] [Abstract][Full Text] [Related]
12. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
Pandey R; Sharma S; Khuller GK
Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles.
Dutt M; Khuller GK
J Antimicrob Chemother; 2001 Jun; 47(6):829-35. PubMed ID: 11389115
[TBL] [Abstract][Full Text] [Related]
14. Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model.
Pandey R; Khuller GK
J Antimicrob Chemother; 2006 Jun; 57(6):1146-52. PubMed ID: 16597631
[TBL] [Abstract][Full Text] [Related]
15. Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery.
Pandey R; Ahmad Z; Sharma S; Khuller GK
Int J Pharm; 2005 Sep; 301(1-2):268-76. PubMed ID: 16023808
[TBL] [Abstract][Full Text] [Related]
16. Poly (DL-lactide-co-glycolide) microparticles as carriers for antimycobacterial drug rifampicin.
Dutt M; Khuller GK
Indian J Exp Biol; 2000 Sep; 38(9):887-94. PubMed ID: 12561946
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
Chavanpatil MD; Patil Y; Panyam J
Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice.
Dutt M; Khuller GK
Antimicrob Agents Chemother; 2001 Jan; 45(1):363-6. PubMed ID: 11121000
[TBL] [Abstract][Full Text] [Related]
19. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
[TBL] [Abstract][Full Text] [Related]
20. The potential of azole antifungals against latent/persistent tuberculosis.
Ahmad Z; Sharma S; Khuller GK
FEMS Microbiol Lett; 2006 May; 258(2):200-3. PubMed ID: 16640573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
